Apollo Hospitals to buy IFC's stake in subsidiary for ₹1,254 crore; shares down

Shares of Apollo Hospitals rose 1.03% to touch an intraday high of ₹7,956.00 apiece on the National Stock Exchange (NSE). The stock opened at ₹7,900.00, up from the previous close of ₹7,874.50. The stock fell 0.57% to ₹7,829.5 apiece at 9:39 AM. The company’s market capitalisation stands at ₹1,12,655.28 crore.

The company's board at its meeting held on Friday approved the execution of definitive share purchase agreements for the acquisition of a little over 41.65 crore equity shares, aggregating to a 30.58% equity stake held jointly by the International Finance Corporation, Washington (IFC), and IFC EAF Apollo Investment Company (IFC EAF) in Apollo Health and Lifestyle Ltd (AHLL), Apollo Hospitals Enterprise Ltd (AHEL), said in a regulatory filing.

Upon completion of the proposed acquisition of shares, AHLL will become a 100% subsidiary of the company, with 99.42% held by Apollo Hospital and the balance in the ESOP pool.

The object of the acquisition is to consolidate ownership and have full control over AHLL's operations, allowing better integration with the firm's diagnostic services and improving operational efficiencies, the filing said.

The board has also approved setting up a comprehensive oncology facility at Gurugram at an investment of ₹573 crore, it added.

Apollo Hospital to set up oncology facility in Gurugram

Apollo Hospitals has announced plans to establish a 100-bed Comprehensive Oncology Centre in Gurugram that will incorporate a next-generation proton therapy system. The cancer centre will form part of the Phase 2 expansion of Apollo’s upcoming 500-bed hospital in Gurugram.

According to the company, Phase 1 of the Gurugram hospital is on track for commissioning by the end of Q4 FY25 / Q1 FY26. The Proton & Integrated Cancer Centre is planned to follow, with a targeted completion timeline of the next four years.

This installation will be Apollo’s third proton therapy facility in India. Citing global projections, the release noted that cancer incidence is expected to rise to an estimated 21.4 million new cases by 2030. It referenced a study in The Lancet Regional Health indicating that, in absolute numbers, India ranks third after China and the US, contributing 7.5% of new cancer incidences and expected to reach 1.5 million new cases this year.

The release also said, Apollo aims to double the scale of its oncology business to over ₹5,000 crore in 3-4 years, driven by high-end personalised care, precision medicine, deeper penetration in major metros and expansion into other cities.

Over the last 5 days, the stock has advanced nearly 1.18%. The scrip has risen 0.48% for the last month. Apollo Hospital shares have zoomed 25.82% for the last 6 months. The stock has touched its 52-week high of ₹7,980 on August 22, 2025 and its 52-week low of ₹6,001 on March 3, 2025.